Nafadotride

Nafadotride

SCHEMBL635866

CCCCN1CCCC1CNC(=O)c1cc(C#N)c2ccccc2c1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 3/20 1.00
KDM4E B2RXH2 2/20 1.00
ALDH1A1 P00352 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C9 P11712 1/20 1.00
ALOX15 P16050 1/20 1.00
MAPK1 P28482 1/20 1.00
SIGMAR1 Q99720 10/20 0.58
DRD2 P14416 2/20 0.55
DRD1 P21728 1/20 0.55
DRD4 P21917 1/20 0.55
DRD5 P21918 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nafadotride SCHEMBL31555135 1.00 DRD3 (1.00) DRD3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL8525891 0.97 DRD3 (0.95) DRD3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL8527772 0.92 KDM4E (0.85) DRD3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL8528795 0.92 DRD3 (0.85) DRD3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL8526940 0.88 DRD3 (0.79) DRD3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL8525946 0.87 KDM4E (0.77) DRD3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL8528369 0.86 DRD3 (0.76) DRD3KDM4EALDH1A1CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL9091591 0.86 KDM4E (0.75) DRD3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL8527263 0.81 KDM4E (0.69) DRD3KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL8526450 0.81 DRD3 (0.68) DRD3KDM4EALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107412-A1 SARCOSPAN MODULATION AND METHODS OF MEAT AND TISSUE CULTURE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-21 WO claimed
US-20250319074-A1 TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME UNIV EAST CAROLINA (US) 2025-10-16 US claimed
EP-3801510-B1 COMPOUNDS INCREASING THE EXPRESSION OF SARCOSPAN FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHY UNIV CALIFORNIA (US) 2025-04-23 EP claimed
US-12220404-B2 Treatment and management of augmentation in restless legs syndrome EAST CAROLINA UNIVERSITY (US) 2025-02-11 US claimed
US-12109204-B2 Methods for treating muscular dystrophies THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-10-08 US claimed
EP-3313407-B1 TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME UNIV EAST CAROLINA (US) 2023-07-19 EP claimed
EP-4178948-A2 FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF Universidade de Santiago de Compostela (ES) 2023-05-17 EP claimed
WO-2023049482-A1 METHODS OF TREATING RESTRICTIVE EATING DISORDERS ARVID THERAPEUTICS (US) 2023-03-30 WO claimed
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 EP claimed
WO-2022023496-A2 FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) 2022-02-03 WO claimed
WO-2006052626-A2 DOPAMINE 3 RECEPTOR AGONIST AND ANTAGONIST TREATMENT OF GASTROINTESTINAL MOTILITY DISORDERS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-05-18 WO claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
WO-2005105839-A2 ESSENTIAL TREMOR DIAGNOSTIC AND TREATMENT INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2005-11-10 WO claimed
EP-1591455-A1 Essential tremor diagnostic and treatment INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2005-11-02 EP claimed
US-20040176467-A1 Method of preventing or reducing the occurrence of symptoms of psychosis VETERANS AFFAIRS, UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE 2004-09-09 US claimed
WO-2003013507-A1 METHOD OF PREVENTING OR REDUCING THE OCCURRENCE OF SYMPTOMS OF PSYCHOSIS THE UNITED STATES OF AMERICA AS REPRESENTED BY DEPARTMENT OF VETERANS AFFAIRS (US) 2003-02-20 WO claimed
EP-0539281-B1 Naphthamides, process for their preparation and their application in the therapeutical field INST NAT SANTE RECH MED (FR) 1998-12-30 EP claimed
EP-0539281-A1 New naphthamides, process for their preparation and their application in the therapeutical field INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1993-04-28 EP claimed